Fate Therapeutics (FATE) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FATE Fate Therapeutics

Watchlist

2.420
+0.130+5.68%

Trading Nov 25 14:00 ET

275.62MMarket Cap-1475P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

FATE Presents Encourgaing Data From Lupus Study, Stock Gains
Zacks Nov 19 13:00 ET
BofA Securities Upgrades Fate Therapeutics to Neutral From Underperform, $3 Price Target
MT NewswiresNov 19 09:53 ET · Ratings
A Quick Look at Today's Ratings for Fate Therapeutics(FATE.US), With a Forecast Between $3 to $10
Moomoo NewsNov 19 08:00 ET · Ratings
Express News | Needham Reiterates Hold on Fate Therapeutics
BenzingaNov 19 04:38 ET
Fate Therapeutics Analyst Ratings
BenzingaNov 19 04:37 ET · Ratings
Barclays Releases a Buy Rating on Fate Therapeutics (FATE)
TipRanksNov 19 03:46 ET · Ratings

Comments

liang wang199

Nov 18 11:21

There will be a big rise soon.

Jaguar8

Nov 18 09:01

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Presents 6-Month Follow-Up Data On First Patient Treated In Phase 1 Autoimmunity Study With Fludarabine-Free Conditioning And FT819 Off-The-Shelf, 1XX CAR T-Cell Product Candidate At ACR Convergence
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies
Patient Treated with Fludarabine-free Conditioning a...

Stock_Drift

Nov 9 13:03

$Fate Therapeutics (FATE.US)$

Jaguar8

Nov 9 12:31

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Fate Therapeutics (NASDAQ: FATE) presented initial clinical and preclinical data for FT825/ONO-8250, a CAR T-cell therapy targeting HER2 in advanced solid tumors. The Phase 1 study's first low-dose cohort of three heavily pre-treated patients showed favorable safety outcomes with ...

Jaguar8

Nov 8 15:03

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics presented preclinical data for FT836, a novel CAR T-cell product candidate targeting MICA/B proteins expressed on cancer cells, at the 2024 SITC Annual Meeting. FT836 incorporates the company's Sword & Shield technology, designed to promote functional persistence without conditioning chemotherapy. The preclinical data demonstrated robust antigen-mediated expansion and durable anti-tumor activity across various solid tumors. The product uniquely ...